AVTX - CIK 0001534120
Avalo Therapeutics, Inc. (AVTX) reported net income of -$78.26M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$78.26M | -122.8% |
| FY 2024 | -$35.13M | -11.4% |
| FY 2023 | -$31.54M | +24.3% |
| FY 2022 | -$41.66M | +50.6% |
| FY 2021 | -$84.38M | -32.9% |
| FY 2020 | -$63.50M | -295.1% |
| FY 2019 | -$16.07M | +59.9% |
| FY 2018 | -$40.05M | -437.4% |
| FY 2017 |
Avalo Therapeutics, Inc. (AVTX) reported net income of -$78.26M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2013 and fiscal 2025, Avalo Therapeutics, Inc.'s net income declined from -$13.05M to -$78.26M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $11.87M |
| +172.1% |
| FY 2016 | -$16.47M | -57.0% |
| FY 2015 | -$10.49M | +34.7% |
| FY 2014 | -$16.06M | -23.1% |
| FY 2013 | -$13.05M | - |